The FDA approved Aemcolo (rifamycin) yesterday for the treatment of travelers’ diarrhea. Aemcolo is an antibacterial drug to treat noninvasive strains of Escherichia coli (E. coli) not complicated by fever or blood in the stool. The FDA estimates 10-40% of travelers worldwide are affected by Travelers’ diarrhea, commonly caused by bacteria in food and water.
Dr. Herbert Dupont, Professor for Infectious Diseases at The University of Texas-Houston School of Public Health and primary investigator said, “given the potential seriousness of Travelers’ Diarrhea and growing resistance to antibiotics that have been in widespread use since the early ‘90s, it’s important to have a new option for treatment. Because AEMCOLO is a minimally absorbed, colon-targeted antibiotic, it will be an important new option for patients.”
Aemcolo will be available in pharmacies in the first quarter of 2019 according to Cosmo Pharmaceuticals’ press release.